OR WAIT 15 SECS
Min Dong, PhD, and his lab are world experts in toxins and how to combat them. They've figured out how Clostridium difficile's most potent toxin gets into cells and zeroed in on the first new botulinum toxin identified since 1969. Now, setting their sights on Shiga and ricin toxins, they've not only identified new potential lines of defense, but also shed new light on a fundamental part of cell biology: glycosylation.
The study, recently published in PLOS Biology, used CRISPR/Cas9 technology to explore what factors in cells are necessary for the toxins to get in. Shiga toxin, a widespread source of food poisoning, is produced by Shigella dysenteriae and some E. coli strains such as O157:H7, which occasionally cause hemolytic uremic syndrome, a serious kidney condition, in children. Ricin is a plant toxin used as a bioterrorism agent.
Shiga and ricin toxins have a similar mechanism of action once inside our tissues, disrupting cells' ability to make proteins. To get in, though, they rely on different entry portals: Shiga toxins use a type of glycolipid (a fatty molecule with an attached sugar) called Gb3 as their receptor, while ricins use a variety of glycans (sugar molecules).
But beyond that, little was known. Dong and first author Songhai Tian, PhD, researchers in Boston Children's Hospital's Department of Urology, hoped to complete the picture.
The research team began with Shiga toxins. They used CRISPR/Cas9 to conduct a genome-wide screen. The screen entailed systematically deleting genes one by one in a cell line, to see if the loss of any of them prevented the toxins from entering.
"This was not possible previously, because the receptor for the toxin isn't found in most cell types," says Dong. "Songhai screened many different cell lines without much success, until he talked to our neighbor, Dr. Rosalyn Adam in the Department of Urology, who happens to have a few bladder cancer cell lines. One of these turns out to be super sensitive to Shiga toxins because it has a high level of Gb3. Finding a good cell model was the first breakthrough in the project."
The second screen, in readily available HeLa cell lines, looked for cell factors required for ricin toxicity.
"The screen approach was very powerful," says Tian. "It identified almost all the known factors for both toxins, as well as some novel factors."
When the team compared the results of the Shiga and ricin screens, they found two factors that both toxin classes require to penetrate cells: the transmembrane proteins TMEM165 and TM9SF2. Both are found in the cell's Golgi apparatus, whose job it is to modify and package large molecules made by the cell. When either was deleted, the cells produced reduced amounts of a group of fatty molecules called glycosphingolipids, including Gb3.
TMEM165 and TM9SF2 are too general in their function to serve as safe targets to try to block with drugs, but they could point the way to other inhibitory molecules that could be targeted.
A third protein, LATMP4a, offers more direct promise. It is specifically required for cells to make Gb3, the receptor used by Shiga toxin. "This protein was not known before, and we think it would make a very good therapeutic target for Shiga toxicity," says Dong.
Dong is equally excited about what the work has to tell us about glycosylation -- the attachment of sugars to large molecules like proteins and lipids. This fundamental biologic process enables our cells to create much more varied molecules with diverse functions, above and beyond what's encoded in our genes, and also has a role in disease.
"We used toxins as a probe to understand a key cellular process," Dong elaborates. "The two new Golgi proteins identified in our screens, TMEM165 and TM9SF2, like regulating the overall environment in the Golgi apparatus. We're now trying to understand what they're regulating specifically."
This isn't the first time one of Dong's toxin investigations has turned up something unexpected: work on C. difficile's toxin B has revealed a potential anti-cancer strategy.
The current study was funded by the National Institutes of Health, the Boston Children's Hospital Intellectual and Developmental Disabilities Research Center, Intelligence Advanced Research Projects Activity (IARPA) and the Burroughs Wellcome Fund. See the paper for a full list of authors and affiliations.
Source: Boston Children's Hospital